Product vision |
- Uncomplicated malaria treatment and resistance management
|
MoA |
|
Key features |
- Fast killing in vitro and in vivo
- No resistant mutants identified
- Low predicted dose (100 mg) and 200 h predicted half-life
|
Challenges |
- Human PK prediction for low clearance compounds
- Synthetic route: Palladium used in two chemical steps
|
Status |
- Metabolite identification ongoing to confirm human PK prediction
- Photosafety study ongoing
|
Next milestone |
- Completion of Good Laboratory Practice (GLP) toxicology programme
|
Previously |
|
MMV Project Director |
|